Correct Answer: C. Pheochromocytoma
Vanillylmandelic acid (VMA) is the primary urinary metabolite of catecholamines (epinephrine and norepinephrine). Pheochromocytoma is a catecholamine-secreting tumor of the adrenal medulla that produces excessive amounts of epinephrine and norepinephrine. These catecholamines undergo hepatic metabolism via catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO), ultimately producing VMA as the major end product. Elevated 24-hour urinary VMA (>7 mg/day) is a classic diagnostic marker for pheochromocytoma. The diagnosis is confirmed by elevated plasma free metanephrines or 24-hour urine metanephrines, followed by imaging (CT/MRI) to localize the tumor. In the Indian context, pheochromocytoma accounts for 0.1–0.2% of hypertension cases but must be ruled out in any patient with paroxysmal hypertension, sweating, palpitations, and headache, as missing this diagnosis can lead to hypertensive crisis during anesthesia or labor.
Why the other options are wrong
A. Carcinoid syndrome — Carcinoid syndrome results from serotonin and other vasoactive amines (5-HT, bradykinin) secreted by neuroendocrine tumors, not catecholamines. The diagnostic marker is elevated 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA), not VMA. While both are neuroendocrine tumors, they have entirely different biochemical pathways and urinary metabolites. B. Diabetic ketoacidosis — DKA is an acute metabolic complication of diabetes characterized by hyperglycemia, ketonemia, and metabolic acidosis. Although stress hormones (including catecholamines) are elevated during DKA, the condition does not cause pathological catecholamine overproduction or significantly elevated urinary VMA. VMA elevation is not a diagnostic or characteristic feature of DKA. D. Alkaptonuria — Alkaptonuria is an autosomal recessive disorder of tyrosine metabolism caused by deficiency of homogentisate 1,2-dioxygenase, leading to accumulation of homogentisic acid (which turns urine dark on standing). This is a disorder of early tyrosine catabolism, not catecholamine metabolism, and does not result in elevated urinary VMA.
High-Yield Facts
- VMA (vanillylmandelic acid) is the major urinary metabolite of catecholamines; normal 24-hour urinary VMA <7 mg/day
- Pheochromocytoma classically presents with triad of paroxysmal headache, profuse sweating, and palpitations with episodic hypertension
- Catecholamine metabolism: epinephrine/norepinephrine → metanephrines (via COMT) → VMA (via MAO); VMA is the final stable end product
- Plasma free metanephrines and 24-hour urine metanephrines are more sensitive (96–99%) than VMA for pheochromocytoma diagnosis
- Rule of 10s: 10% bilateral, 10% extra-adrenal (paraganglioma), 10% malignant, 10% familial (MEN2A/2B, NF1, SDH mutations)
- Hypertensive crisis risk during anesthesia, labor, or abdominal manipulation in undiagnosed pheochromocytoma due to massive catecholamine release
Mnemonics
VMA = Catecholamine Marker VMA (Vanillyl Mandelic Acid) → Pheochromocytoma. Remember: VMA is the final urine metabolite of catecholamines after COMT and MAO action. When you see 'VMA in urine,' think catecholamine excess → pheochromocytoma. Neuroendocrine Tumor Markers Carcinoid = 5-HIAA (serotonin pathway); Pheochromocytoma = VMA/metanephrines (catecholamine pathway); Medullary thyroid cancer = calcitonin. Different tumors, different amines, different markers.
NBE Trap
NBE may pair pheochromocytoma with carcinoid syndrome because both are neuroendocrine tumors with catecholamine-like symptoms (hypertension, flushing, sweating). The trap is confusing the biochemical pathway: carcinoid secretes serotonin (5-HIAA marker), while pheochromocytoma secretes catecholamines (VMA marker).
Clinical Pearl
In Indian practice, any patient presenting with resistant hypertension (BP uncontrolled on ≥3 antihypertensives) or paroxysmal hypertension with sweating episodes should be screened for pheochromocytoma with 24-hour urine VMA or plasma metanephrines before surgery or anesthesia, as intraoperative catecholamine surge can trigger life-threatening hypertensive crisis and arrhythmias.
_Reference: KD Tripathi Ch. 12 (Catecholamine Metabolism); Harrison Ch. 405 (Pheochromocytoma); Robbins Ch. 20 (Adrenal Medulla Tumors)_